Evidence map›Paper›PMID 28174294›Full record

ArticleThe oncologist2017

Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.

Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher and 4 more

Open access · bronzeAbstract readHistorical Article
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Peter DallDepartment of Obstetrics and Gynaecology and Breast Cancer Center, Klinikum Lüneburg, Lüneburg, Germany peter.dall@klinikum-lueneburg.de.
Thorsten KochBreast Center, Klinikum Nürnberg, Nürnberg, Germany.
Thomas GöhlerOnkozentrum Dresden/Freiberg, Dresden, Germany.
Johannes SelbachOncology Practice, Duisburg, Germany.
Andreas AmmonOncology Practice, Göttingen, Germany.
Jochen EggertOncology Practice, Moers, Germany.
Nidal GazawiGyneco-Oncology Practice, Leipzig, Germany.
Daniela RezekGynecology, Marien-Hospital, Wesel, Germany.
Arthur WischnikDepartment of Gynecology, Klinikum Augsburg, Augsburg, Germany.
Carsten HielscherGyneco-Oncology Practice, Stralsund, Germany.
Stella KeitelRoche Pharma AG, Grenzach-Wyhlen, Germany.
Ursula CirrincioneWiSP Research Institute, Langenfeld, Germany.
Axel HinkeWiSP Research Institute, Langenfeld, Germany.
Gabriele Feisel-SchwickardiDepartment of Obstetrics and Gynaecology and Breast Cancer Center, Klinikum Kassel, Kassel, Germany.
Klinikum Kassel · DEKlinikum Lüneburg · DEMarien Hospital Wesel · DENuremberg Hospital · DEOnkozentrum Dresden · DERoche Pharma AG (Germany) · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies. PATIENTS AND

methodsBetween 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.

resultsAmong 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%-91.1%) and 82.8% (95% CI, 81.2%-84.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%-97.6%) and 90.0% (95% CI, 88.6%-91.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade ≥2 and ≥3 was observed in 2.5% and less than 1% of patients, respectively.

conclusionThe maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).

Indexed as

AgedBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGermanyHistory, 21st CenturyHumansProspective StudiesTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabadjuvant chemotherapybreast cancerhuman epidermal growth factor receptor 2observational studytrastuzumab

Identifiers

PMID28174294
PMCPMC5330700
OpenAlexW2586164340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.